Yuhan Corporation said it has signed a domestic supply agreement with Bayer Korea for Bepanthen Ointment and Canesten.

Bepanthen Ointment is the first non-steroidal skin treatment containing dexpanthenol and is currently the world's best-selling product in the dermatology sector. It is widely used to soothe sensitive skin and restore damaged skin barriers, making it suitable for treating various skin conditions across all age groups, including diaper rash in infants, acute and chronic dermatitis (such as dry skin conditions), wounds, eczema, and sunburn.

Canesten, which contains clotrimazole as its active ingredient, is an antifungal treatment for skin surface fungal infections and Candida-related vaginitis. Available in various forms such as cream, pessary, and powder, Canesten is the world's top-selling treatment for Candida vaginitis and vulvitis, positioning itself as a leading solution for women's health management in daily life.

Under the accord, Yuhan and Bayer Korea will commence co-promotion activities for Bepanthen Ointment and Canesten products starting in February.

Yuhan Corp. aims to further expand its market share in the local dermatology and women’s health sectors, particularly in the treatment of vaginitis and vulvitis.

"Bepanthen Ointment and Canesten are globally recognized products that have significantly contributed to disease treatment worldwide,” Yuhan Corp. CEO Cho Wook-je said. “We hope that this partnership will create synergy between the strengths of both companies, allowing Korean consumers easier access to these high-quality products."

Bayer Korea Consumer Health Country Division Head Oh Young-keyoung also said, "We are pleased to collaborate with Yuhan Corp., which possesses excellent sales capabilities and a robust distribution network.”

This partnership will enhance accessibility to Bayer's products that address common skin and women's health conditions, ultimately contributing to a healthier everyday life for Korean consumers, Oh added.